Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery

PHASE4CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

May 11, 2021

Primary Completion Date

July 4, 2023

Study Completion Date

October 25, 2023

Conditions
Ischemia With Non-Obstructive Coronary ArteryAngina PectorisCoronary Heart DiseaseX Syndrome, Angina
Interventions
RADIATION

Shexiang Baoxin pill(MUSKARDIA)

On the basis of routine treatment, MUSK Pills were added to 4 capsules / day, 3 times per day until the end of follow-up.

RADIATION

Placebo

On the basis of routine treatment, Placebo were added to 4 capsules / day, 3 times per day until the end of follow-up.

Trial Locations (1)

200003

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai Changzheng Hospital

OTHER

collaborator

The Second People's Hospital Of Bengbu

UNKNOWN

collaborator

The Second Affiliated Hospital of Jiaxing University

OTHER

collaborator

Zibo Municipal Hospital

OTHER

collaborator

Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

OTHER

collaborator

Shanxi Cardiovascular Hospital

OTHER

collaborator

The First Hospital of Hebei Medical University

OTHER

collaborator

Tangshan Central Hospital

OTHER

collaborator

Tie Fa Coal Group Ceneral Hospital of Liaoning Health Industry Group

UNKNOWN

collaborator

Ceneral Hospital Of Benxi Iron And Steel of Liaoning Health Industry Group

UNKNOWN

collaborator

General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group

UNKNOWN

lead

Shanghai Hutchison Pharmaceuticals Limited

INDUSTRY